 Cabaletta Bio Inc NASDAQ: CABA has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris mPV. Related: Cabaletta Announced Favorable Safety Profile From First Cohort Of Phase 1 Study. 